To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers (CAM-PLEX)
To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.
Sponsor: CCTU- Cancer Theme
Listed as NCT02179970, this PHASE1 trial focuses on Colorectal Cancer Metastatic and Ovarian Serous Adenocarcinoma and remains completed. Sponsored by CCTU- Cancer Theme, it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2019 — Aug 2019 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Aug 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CCTU- Cancer Theme
- CRUK Cambridge Institute
- Lustgarten Foundation
- National Institute for Health Research, United Kingdom
- Sanofi
- Stand Up To Cancer
For direct contact, visit the study record on ClinicalTrials.gov .